JUN 20, 2018 9:00 AM PDT

Identifying Driver Alterations and Therapeutic Options in Cancer

Speaker
  • Head of Knowledge Systems, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
    Biography
      Nikolaus Schultz leads the development of the cBioPortal for Cancer Genomics, a popular resource for the visualization and analysis of large-scale cancer genomics data sets. His research focuses on identifying the genomic alterations that underlie different types of cancer. He is involved in several projects of The Cancer Genome Atlas (TCGA) and is an investigator in the Stand Up To Cancer (SU2C) Prostate Cancer Dream Team.

      Dr. Schultz is an Associate Attending Computational Oncologist in the Department of Epidemiology and Biostatistics and an affiliate member of the Human Oncology and Pathogenesis Program. He is the Head of Knowledge Systems in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology.

    Abstract

    With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for clinical support tools that aid clinicians in their decision making. To this end, we are developing tools for the visualization and interpretation of genomic variants in the context of clinical annotation. 

    To this end, we have developed OncoKB, a precision oncology knowledge base that annotates the effects and treatment implications of somatic mutations in cancer. OncoKB annotations are available for research use via oncokb.org, and the database is used to annotate the sequencing reports of of tumor samples from patients at Memorial Sloan Kettering Cancer Center. 

    We are also co-developers of the cBioPortal for Cancer Genomics. The cBioPortal is an open source software tool that provides intuitive visualization and analysis of cancer genomics data, allowing cross-cohort analyses but also the viewing and interpretation of individual tumor samples. The public site at cbioportal.org provides access to published sequencing data from more than 25,000 tumor samples, and private instances of cBioPortal are installed at multiple academic research centers, in hospitals, and pharmaceutical companies. Annotations from OncoKB as well as other sources, such as COSMIC, CIViC, and cancerhotspots.org, are integrated into cBioPortal to facilitate the interpretation of variants in cancer cohorts and individual patient samples.

    This presentation will summarize the challenges of precision oncology and cancer genomics research and will present how OncoKB and the cBioPortal for Cancer Genomics can be used to overcome some of these challenges.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources